Psychotherapy Enhancement for Therapeutic Community (TC) Retention - 1

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2005 by National Institute on Drug Abuse (NIDA).
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00086398
First received: July 1, 2004
Last updated: November 3, 2005
Last verified: November 2005
  Purpose

The purpose of this study is to evaluate the efficacy of Dual Focus Schema Therapy in comparison to Individual Drug Counseling as 6-month manualized individual behavioral therapy enhancements to the orientation/early treatment process of Therapeutic Community (TC) residents.


Condition Intervention Phase
Substance-Related Disorders
Behavioral: Behavior Therapy
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Factorial Assignment
Primary Purpose: Treatment
Official Title: Psychotherapy Enhancement for TC Retention

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Retention
  • Psychosocial functioning

Estimated Enrollment: 100
Study Start Date: September 2001
Detailed Description:

Therapeutic Community (TC) treatment can be effective psychosocial modality for addiction, but premature dropout remains a major problem. Personality disorders are very common in residential programs, and TCs regard personality disturbance as core to all people with addiction. Severe personality dysfunction is associated with higher dropout rates from TCs, and adding cognitive-behavioral treatments may improve retention and outcome. We hypothesize that severe personality disturbance causes significant problems with an individual?s initial adjustment and effective utilization of TC processes and techniques. We predict that a behavioral therapy that targets personality pathology will result in better early retention and engagement than will a more standard addiction counseling approach.

To begin to improve retention, TC research must begin to systematically evaluate the impact of adding interventions targeted at decreasing premature dropouts through controlled clinical trials. We have developed the first empirically tested treatment manual for the full range of personality disorders in substance abusers and propose to conduct a randomized clinical trial to evaluate the efficacy of Dual Focus Schema Therapy in comparison to Individual Drug Counseling as 6-month manualized individual behavioral therapy enhancements to the orientation/early treatment process of 100 TC residents. In addition to evaluating retention differences, we will analyze the rate and degree of change for these two conditions monthly and at 6, 12, 18, and 24-month follow-up for psychological indicators related to personality disorder and therapeutic processes related to the TC.

  Eligibility

Ages Eligible for Study:   15 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Admission for residential TC treatment at APT Residential Services Division

Inclusion Criteria:

Adolescent or adult substance abuser; provide 2 or more contacts; ability to read and speak English

Exclusion Criteria:

Acute suicidality, homicidality, psychosis, mania

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00086398

Contacts
Contact: Samuel Ball, Ph.D. (203)937-3486 samuel.ball@yale.edu

Locations
United States, Connecticut
APT Residential Services Division Recruiting
New Haven, Connecticut, United States, 06519
Contact: Lisa Maccarelli, Ph.D.    203-337-9943 ext 210    lisa.maccarelli@yale.edu   
Sponsors and Collaborators
Investigators
Principal Investigator: Samuel Ball, Ph.D. APT Foundation, Inc.
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00086398     History of Changes
Other Study ID Numbers: NIDA-14967-1, R01-14967-1
Study First Received: July 1, 2004
Last Updated: November 3, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders

ClinicalTrials.gov processed this record on August 26, 2014